<DOC>
	<DOCNO>NCT02181764</DOCNO>
	<brief_summary>The objective study assess safety tolerability KRN23 single subcutaneous ( SC ) administration subject X-linked hypophosphatemic rickets/osteomalacia ( XLH ) Japan Korea .</brief_summary>
	<brief_title>A Study KRN23 Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia</brief_title>
	<detailed_description />
	<mesh_term>Rickets</mesh_term>
	<mesh_term>Osteomalacia</mesh_term>
	<mesh_term>Rickets , Hypophosphatemic</mesh_term>
	<mesh_term>Familial Hypophosphatemic Rickets</mesh_term>
	<criteria>1 . 18 year old 2 . Patients XLH 1 . Have active infection chronic inflammatory disease 2 . Have uncontrolled hypertension 3 . Have uncontrolled diabetes mellitus 4 . History known immunodeficiency 5 . Use pharmacologic vitamin D metabolite analog within 21 day prior screen screen 6 . Use phosphate , calcium preparation , calcimimetics , aluminum hydroxide antacid , thiazide diuretic , acetazolamide , phosphate , calcium , and/or vitamin Dcontaining supplement within 10 day prior screen screen 7 . Pregnant lactating female , woman possibly pregnant patient intention utilize adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>XLH</keyword>
</DOC>